Renal glucuronidation and multidrug resistance protein 2-/ multidrug resistance protein 4-mediated efflux of mycophenolic acid: Interaction with cyclosporine and tacrolimus

Translational Research

Volumn 164, Issue 1, 2014, Pages 46-56

  El Sheikh, Azza A K ^a   Koenderink, Jan B ^b   Wouterse, Alfons C ^b   Van Den Broek, Petra H H ^b   Verweij, Vivienne G M ^b   Masereeuw, Rosalinde ^b   Russel, Frans G M ^b  

^a Minia University   (Egypt)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXY MYCOPHENOLIC ACID GLUCURONIDE; CYCLOSPORIN; GLUCURONIDE; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 4; MYCOPHENOLIC ACID; TACROLIMUS; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CYTOTOXICITY; DRUG DETOXIFICATION; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG INTERACTION; DRUG TRANSPORT; EMBRYO; GLOMERULUS FILTRATION RATE; HEK293 CELL LINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY HOMOGENATE; KIDNEY PERFUSION; KIDNEY TUBULE EXCRETION; LIQUID CHROMATOGRAPHY; MALE; MICTURITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; URINARY EXCRETION;

ANIMALS; CYCLOSPORINE; DRUG INTERACTIONS; GENE EXPRESSION REGULATION; GLUCURONIDES; HEK293 CELLS; HUMANS; KIDNEY; MALE; MICE; MICE, KNOCKOUT; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MYCOPHENOLIC ACID; ORGAN CULTURE TECHNIQUES; RATS; RATS, WISTAR; TACROLIMUS;

EID: 84902532593     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2014.01.006     Document Type: Article

References (49)

1. M.C. Villarroel, M. Hidalgo, and A. Jimeno Mycophenolate mofetil: an update Drugs Today (Barc) 45 2009 521 532
2. S.M. Flechner Reviewing the evidence for de novo immunosuppression with sirolimus Transplant Proc 40 2008 S25 S28
3. P.M. Stassen, C.G. Kallenberg, and C.A. Stegeman Use of mycophenolic acid in non-transplant renal diseases Nephrol Dialysis Transplant 22 2007 1013 1019
4. M. Shipkova, C.P. Strassburg, and F. Braun et al. Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes Br J Pharmacol 132 2001 1027 1034
5. M. Shipkova, V.W. Armstrong, M. Oellerich, and E. Wieland Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability Expert Opin Drug Metab Toxicol 1 2005 505 526
6. F.A. Elbarbry, and A.S. Shoker Therapeutic drug measurement of mycophenolic acid derivatives in transplant patients Clin Biochem 40 2007 752 764
7. B.C. de Winter, T. van Gelder, F. Sombogaard, L.M. Shaw, R.M. van Hest, and R.A. Mathot Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients J Pharmacokinet Pharmacodynam 36 2009 541 564
8. C.E. Staatz, and S.E. Tett Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients Clin Pharmacokinet 46 2007 13 58
9. G. Filler, N. Lepage, B. Delisle, and I. Mai Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients Therapeutic Drug Monit 23 2001 514 519
10. T. Van Gelder, J. Klupp, M.J. Barten, U. Christians, and R.E. Morris Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid Ther Drug Monit 23 2001 119 128
11. M. Deters, G. Kirchner, T. Koal, K. Resch, and V. Kaever Influence of cyclosporine on the serum concentration and biliary excretion of mycophenolic acid and 7-O-mycophenolic acid glucuronide Ther Drug Monit 27 2005 132 138
12. M. Kobayashi, H. Saitoh, M. Kobayashi, K. Tadano, Y. Takahashi, and T. Hirano Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats J Pharmacol Exp Ther 309 2004 1029 1035
13. I.S. Westley, L.R. Brogan, R.G. Morris, A.M. Evans, and B.C. Sallustio Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine Drug Metab Dispos 34 2006 261 266
14. D.A. Hesselink, R.M. van Hest, and R.A. Mathot et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2 Am J Transplant 5 2005 987 994
15. L. Chen, and K.W. Pankiewicz Recent development of IMP dehydrogenase inhibitors for the treatment of cancer Curr Opin Drug Discov Dev 10 2007 403 412
16. Y. Takekuma, H. Kakiuchi, and K. Yamazaki et al. Difference between pharmacokinetics of mycophenolic acid (MPA) in rats and that in humans is caused by different affinities of MRP2 to a glucuronized form J Pharm Pharm Sci 10 2007 71 85
17. A.A. El-Sheikh, R. Masereeuw, and F.G. Russel Mechanisms of renal anionic drug transport Eur J Pharmacol 585 2008 245 255
18. F.G. Russel, J.B. Koenderink, and R. Masereeuw Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules Trends Pharmacol Sci 29 2008 200 207
19. C.G. Patel, K. Ogasawara, and F. Akhlaghi Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus Xenobiotica 43 2013 229 235
20. A.A.K. El-Sheikh, J.J.M.W. van den Heuvel, J.B. Koenderink, and F.G.M. Russel Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport J Pharmacol Exp Ther 320 2007 229 235
21. R. Masereeuw, S. Notenboom, P.H. Smeets, A.C. Wouterse, and F.G. Russel Impaired renal secretion of substrates for the multidrug resistance protein 2 in mutant transport-deficient (TR-) rats J Am Soc Nephrol 14 2003 2741 2749
22. S. Heemskerk, A.C. Wouterse, F.G. Russel, and R. Masereeuw Nitric oxide down-regulates the expression of organic cation transporters (OCT) 1 and 2 in rat kidney during endotoxemia Eur J Pharmacol 584 2008 390 397
23. A. Nakamura, M. Nakajima, H. Yamanaka, R. Fujiwara, and T. Yokoi Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines Drug Metab Dispos 36 2008 1461 1464
24. K. Walton, J.L. Dorne, and A.G. Renwick Uncertainty factors for chemical risk assessment: interspecies differences in glucuronidation Food Chem Toxicol 39 2001 1175 1190
25. W.X. Zhang, B. Chen, and Z. Jin et al. Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients Xenobiotica 38 2008 1422 1436
26. R.H. van Schaik, M. van Agteren, and J.W. de Fijter et al. UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients Clin Pharmacol Ther 86 2009 319 327
27. T. Fukuda, J. Goebel, and S. Cox et al. UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients Ther Drug Monit 34 2012 671 679
28. D.W. Mudge, B.A. Atcheson, P.J. Taylor, P.I. Pillans, and D.W. Johnson Severe toxicity associated with a markedly elevated mycophenolic acid free fraction in a renal transplant recipient Ther Drug Monit 26 2004 453 455
29. J. Wang, M. Figurski, L.M. Shaw, and G.J. Burckart The impact of P-glycoprotein and Mrp2 on mycophenolic acid levels in mice Transplant Immunol 19 2008 192 196
30. M. Miura, H. Kagaya, and S. Satoh et al. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients Ther Drug Monit 30 2008 559 564
31. H. Michelon, J. Konig, and A. Durrbach et al. SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients Pharmacogenomics 11 2010 1703 1713
32. N. Picard, L. Levoir, F. Lamoureux, S.W. Yee, K.M. Giacomini, and P. Marquet Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters Xenobiotica 41 2011 752 757
33. K.R. Robillard, M.T. Hoque, and R. Bendayan Expression of ATP-binding cassette membrane transporters in rodent and human Sertoli cells: relevance to the permeability of antiretroviral therapy at the blood-testis barrier J Pharmacol Exp Ther 340 2012 96 108
34. M.S. Warren, N. Zerangue, and K. Woodford et al. Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human Pharmacol Res 59 2009 404 413
35. T. Fukuda, H.I. Brunner, A.C. Sagcal-Gironella, and A.A. Vinks Nonsteroidal anti-inflammatory drugs may reduce enterohepatic recirculation of mycophenolic acid in patients with childhood-onset systemic lupus erythematosus Ther Drug Monit 33 2011 658 662
36. H.A. Mutsaers, L.P. van den Heuvel, and L.H. Ringens et al. Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations PLoS One 6 2011 e18438
37. M. Li, H. Yuan, and N. Li et al. Identification of interspecies difference in efflux transporters of hepatocytes from dog, rat, monkey and human Eur J Pharm Sci 35 2008 114 126
38. R. Bullingham, S. Monroe, A. Nicholls, and M. Hale Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration J Clin Pharmacol 36 1996 315 324
39. H. Shiratani, M. Katoh, M. Nakajima, and T. Yokoi Species differences in UDP-glucuronosyltransferase activities in mice and rats Drug Metab Dispos 36 2008 1745 1752
40. T. Li, Y. Zheng, and F. Fu et al. Assessment of UDP- glucuronosyltransferase catalyzed formation of Picroside II glucuronide in microsomes of different species and recombinant UGTs Xenobiotica 41 2011 530 537
41. Y. Tanaka, C. Chen, J.M. Maher, and C.D. Klaassen Ischemia-reperfusion of rat livers decreases liver and increases kidney multidrug resistance associated protein 2 (Mrp2) Toxicol Sci 101 2008 171 178
42. C. Liu, T. Schreiter, and A. Frilling et al. Cyclosporine A, FK-506, 40-0-[2-hydroxyethyl]rapamycin and mycophenolate mofetil inhibit proliferation of human intrahepatic biliary epithelial cells in vitro World J Gastroenterol 11 2005 7602 7605
43. N. Picard, A. Premaud, A. Rousseau, M.Y. Le, and P. Marquet A comparison of the effect of cyclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients Br J Clin Pharmacol 62 2006 477 484
44. H. Kagaya, M. Miura, and S. Satoh et al. No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients J Clin Pharm Ther 33 2008 193 201
45. T. Naito, Y. Mino, and A. Otsuka et al. Impact of calcineurin inhibitors on urinary excretion of mycophenolic acid and its glucuronide in kidney transplant recipients J Clin Pharmacol 49 2009 710 718
46. K. Zucker, A. Tsaroucha, L. Olson, V. Esquenazi, A. Tzakis, and J. Miller Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation Ther Drug Monit 21 1999 35 43
47. I.S. Westley, R.G. Morris, A.M. Evans, and B.C. Sallustio Glucuronidation of mycophenolic acid by Wistar and Mrp2-deficient TR- rat liver microsomes Drug Metab Dispos 36 2008 46 50
48. A. Balogh, U. Merkel, and D. Muller Can xipamide or tacrolimus inhibit the glucuronidation of mycophenolic acid in rat liver slices? Exp Toxicol Pathol 54 2003 375 379
49. M. Naesens, D.R. Kuypers, and F. Streit et al. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients Clin Pharmacol Ther 80 2006 509 521